



## Financial Tearsheet

### CORPORATE PROFILE

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) is a biopharmaceutical company focused on the development and commercialization of innovative medicines that provide unique and meaningful advantages to people with renal disease and their healthcare providers. In September 2014, the U.S. Food and Drug Administration approved Keryx's first medicine. Patients have been and continue to be at the center of our 17-year corporate history.

Keryx established its corporate headquarters in Boston to support the U.S. launch of its first medicine. Joining Boston's pioneering biotech community has given us the opportunity to bring together a seasoned talent pool of innovative minds and resources that will allow us to continue toward our goal of building a leading renal company. We are a rapidly growing company, with approximately 185 full-time employees across Boston, New York, and our field team.

### PRIMARY IR CONTACT

Lora Pike  
Senior Director, Investor  
Relations  
**Phone:** 617-466-3511  
**E-mail:** [IR@keryx.com](mailto:IR@keryx.com)

### STOCK PERFORMANCE

#### KERX (Common)

<b>Exchange</b>	NASDAQ (US Dollar)
<b>Price</b>	<b>\$6.85</b>
<b>Change (%)</b>	<b>▲ 0.11 (1.63%)</b>
<b>Volume</b>	418,985
<b>52 Week Low</b>	\$4.03
<b>Market Cap</b>	\$813,439,082
<b>Rolling EPS</b>	-1.71
<b>PE Ratio</b>	N/A
<b>Shares Outstanding</b>	118,750,231

Data as of 08/23/17 4:00 p.m. ET



### RECENT HEADLINES & EVENTS

08/04/17 - 8:32 a.m.

[Keryx Biopharmaceuticals to Webcast its Presentation at Canaccord Genuity's 37th Annual Growth Conference on August 9, 2017](#)

07/27/17 - 7:01 a.m.

[Keryx Biopharmaceuticals Announces Second Quarter 2017 Financial Results and Increased 2017 U.S. Product Sales Guidance](#)

There are currently no events scheduled.

07/19/17 - 8:32 a.m.

Keryx Biopharmaceuticals to Host Conference Call of Second  
Quarter 2017 Financial Results on Thursday, July 27, 2017

---

## SEC FILINGS

Filing Date	Form
08/01/17	4
08/01/17	4
08/01/17	4
08/01/17	4

## CORPORATE GOVERNANCE

Ron Bentsur Chief Executive Officer

James Oliviero Chief Financial Officer

Powered By **EDGAR** Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed